BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26620414)

  • 21. Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin.
    Nair JS; Musi E; Schwartz GK
    Clin Cancer Res; 2017 Aug; 23(15):4301-4311. PubMed ID: 28314790
    [No Abstract]   [Full Text] [Related]  

  • 22. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
    Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
    Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
    [No Abstract]   [Full Text] [Related]  

  • 23. Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells.
    Uddin MH; Li Y; Khan HY; Muqbil I; Aboukameel A; Sexton RE; Reddy S; Landesman Y; Kashyap T; Azmi AS; Heath EI
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models.
    Gravina GL; Marampon F; Sherris D; Vittorini F; Di Cesare E; Tombolini V; Lenzi A; Jannini EA; Festuccia C
    Prostate; 2014 Jun; 74(8):852-68. PubMed ID: 24715588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer.
    Gao J; Azmi AS; Aboukameel A; Kauffman M; Shacham S; Abou-Samra AB; Mohammad RM
    Oncotarget; 2014 Jun; 5(11):3444-54. PubMed ID: 24899509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KPT-330 has antitumour activity against non-small cell lung cancer.
    Sun H; Hattori N; Chien W; Sun Q; Sudo M; E-Ling GL; Ding L; Lim SL; Shacham S; Kauffman M; Nakamaki T; Koeffler HP
    Br J Cancer; 2014 Jul; 111(2):281-91. PubMed ID: 24946002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.
    London CA; Bernabe LF; Barnard S; Kisseberth WC; Borgatti A; Henson M; Wilson H; Jensen K; Ito D; Modiano JF; Bear MD; Pennell ML; Saint-Martin JR; McCauley D; Kauffman M; Shacham S
    PLoS One; 2014; 9(2):e87585. PubMed ID: 24503695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Scoparone exerts anti-tumor activity against DU145 prostate cancer cells via inhibition of STAT3 activity.
    Kim JK; Kim JY; Kim HJ; Park KG; Harris RA; Cho WJ; Lee JT; Lee IK
    PLoS One; 2013; 8(11):e80391. PubMed ID: 24260381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
    Azmi AS; Muqbil I; Wu J; Aboukameel A; Senapedis W; Baloglu E; Bollig-Fischer A; Dyson G; Kauffman M; Landesman Y; Shacham S; Philip PA; Mohammad RM
    Sci Rep; 2015 Nov; 5():16077. PubMed ID: 26536918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway.
    Zhao C; Yang ZY; Zhang J; Li O; Liu SL; Cai C; Shu YJ; Pan LJ; Gong W; Dong P
    J Transl Med; 2022 Sep; 20(1):434. PubMed ID: 36180918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.
    Cheng Y; Holloway MP; Nguyen K; McCauley D; Landesman Y; Kauffman MG; Shacham S; Altura RA
    Mol Cancer Ther; 2014 Mar; 13(3):675-86. PubMed ID: 24431073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
    Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
    Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
    [No Abstract]   [Full Text] [Related]  

  • 33. Ginkgetin inhibits the growth of DU-145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity.
    Jeon YJ; Jung SN; Yun J; Lee CW; Choi J; Lee YJ; Han DC; Kwon BM
    Cancer Sci; 2015 Apr; 106(4):413-20. PubMed ID: 25611086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
    Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels.
    Tan M; Wettersten HI; Chu K; Huso DL; Watnick T; Friedlander S; Landesman Y; Weiss RH
    Am J Physiol Renal Physiol; 2014 Dec; 307(11):F1179-86. PubMed ID: 25234309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polypurine reverse Hoogsteen hairpins as a gene therapy tool against survivin in human prostate cancer PC3 cells in vitro and in vivo.
    Rodríguez L; Villalobos X; Dakhel S; Padilla L; Hervas R; Hernández JL; Ciudad CJ; Noé V
    Biochem Pharmacol; 2013 Dec; 86(11):1541-54. PubMed ID: 24070653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus.
    Tajiri N; De La Peña I; Acosta SA; Kaneko Y; Tamir S; Landesman Y; Carlson R; Shacham S; Borlongan CV
    CNS Neurosci Ther; 2016 Apr; 22(4):306-15. PubMed ID: 26842647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis.
    Zhu ZC; Liu JW; Yang C; Zhao M; Xiong ZQ
    Cell Death Dis; 2019 May; 10(6):395. PubMed ID: 31113936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo.
    Shen G; Chen J; Zhou Y; Wang Z; Ma Z; Xu C; Jiang M
    Cell Physiol Biochem; 2018; 50(2):798-809. PubMed ID: 30308485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
    Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.